Skip to main content

[Webinar] Improving Management of Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

By December 7, 2018February 18th, 2019No Comments
Improving Management of Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

Recorded On
Thursday, December 6th, 2018
1:00 – 2:00 pm EST

Improving Management of Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

In 2018, there will be an estimated 164,690 new cases of prostate cancer (PC) in the U.S. and approximately 29,430 patients will die of the disease, making it the third-leading cause of cancer death in men (American Cancer Society [ACS], 2018). The majority of men with PC are treated with curative intent (i.e., with radical prostatectomy or radiation therapy) with good outcomes, but a fraction of men with locoregional PC will develop progressive disease. Men who have initial PSA/biochemical recurrence after curative treatment are a heterogeneous group of individuals with good overall prognosis, including a median metastasis-free survival (MFS) >8 years and a median overall survival (OS) of >23 years (Rozet et al., 2016).

Approximately 10%-20% of prostate cancer patients develop castration-resistant PC (CRPC) within approximately 5 years of follow-up. Decisions about clinical management (i.e., when to start treatment) are challenging because it is unclear which patients will have shorter versus longer survival, and metastatic disease is not always reliably detected with imaging (Rozet et al., 2016).

Multiple new targeted agents, including immunotherapy, second-generation hormone therapy, and androgen biosynthesis inhibitors have been recently approved. Two recently published studies (PROSPER and SPARTAN) have changed the standard of care for patients with nmCRPC.

Learning Objectives

At the conclusion of this educational initiative, participants should be able to:

  • Utilize new data regarding the evidence-based management of patients with nmCRPC
  • Discuss implications of decisions regarding timing and treatment sequencing for patients with nmCRPC on subsequent therapy
  • Identify ongoing late phase clinical trials in nmCRPC
  • Implement strategies to manage education and symptoms for men with nmCRPC


Mary W. Dunn, NPMary W. Dunn, RN, MSN, OCN, NP-C
Adjunct Faculty
University of North Carolina, School of Nursing



Megan McNamara, MDMegan McNamara, MD
Division of Medical Oncology, Department of Medicine
Duke Cancer Institute


Webinar Agenda (All times in EST)

One-Hour Webcast Topics:

1:00 – 1:25 pm Evolving Evidence-Based Treatment Paradigms for nmCRPC (including late-stage clinical trials for nmCRPC) Megan McNamara, MD
 1:25 – 1:50 pm Supportive Care for the Treatment of men with CRPC Mary W. Dunn, RN, MSN, OCN, NP-C
1:50 – 2:00 pm Question & Answer Session Panel and webinar participants

Who Should Attend?

This activity is intended for urologists, medical oncologists, urology/oncology nurses, and nurse navigators.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Carevive Systems, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty Disclosures

Megan McNamara, MD Contracted Research: Funds directed towards institution from Bayer, Janssen, Clovis, Agensys, and Seattle Genetics; Speaker’s Bureau: Bayer

Mary W. Dunn, NP has no real or apparent conflicts of interest to report.

Planners and Managers

The PIM planners and managers have nothing to disclose. The Carevive planners and managers have nothing to disclose.

Fee Information

There is no fee for this educational activity.

This activity is supported by an independent educational grant from Astellas.

Jointly provided by Postgraduate Institute for Medicine and Carevive Systems, Inc. Postgraduate Institute for Medicine and Carevive Logos

Slide Presentation